Commentary: British biotech industry lagging

09/14/2004 | Guardian (London), The

Heather Tomlinson of The Guardian writes that her country's slow growth in the biotechnology sector is partly the result of U.S. firms reaping most of the financial gains from highly effective drugs for rheumatoid arthritis, such as Remicade, Enbrel and Humira, all developed by British scientists. She says the U.K. biotechnology industry lags behind because, unlike its American counterparts, it fails to make its research findings commercially viable, and many companies are unwilling to take the financial risk necessary to bring new therapies to the market.

View Full Article in:

Guardian (London), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Systems Test - V&V Engineer - 14000008LS
Abbott
San Jose, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Director, Antibiotics and Innovation Project
The Pew Charitable Trusts
Washington, DC